Alnylam Ready To Expand TTR Franchise With Positive Cardiomyopathy Results
Supplemental Onpattro US Filing Planned For Late 2022
ATTR amyloidosis patients with cardiomyopathy had statistically significant functional and quality of life improvements when treated with Onpattro (patisiran) in the Phase III APOLLO-B study.
